Back to VSTMView full pipeline
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
0 competitors in Low Grade Serous Ovarian Cancer
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
avutometinib (VS-6766)Phase 2
Low Grade Ovarian Serous Adenocarcinoma
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2
KRAS Activating Mutation
Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2
Low Grade Serous Ovarian Cancer
defactinib (VS-6063)Phase 2
Non Small Cell Lung Cancer
VS-7375Phase 2
Pancreatic Ductal Adenocarcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts